Your browser doesn't support javascript.
loading
Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?
Pourmir, I; Nebbache, R; Champiat, S; Lambotte, O.
Afiliação
  • Pourmir I; Thoracic Oncology Department, Georges Pompidou European Hospital, Paris CARPEM Cancer Institute, AP-HP Centre, Université Paris Cité, Paris; INSERM Immunotherapy and Anti-Angiogenic Therapy in Oncology, PARCC, Paris.
  • Nebbache R; Faculty of Health, Sorbonne Université, Paris.
  • Champiat S; Drug Development Department (DITEP), Gustave Roussy, Paris-Saclay University, Villejuif; INSERM, U1015, Paris-Saclay University, Villejuif.
  • Lambotte O; Paris Saclay University, AP-HP, Department of Internal Medicine and Clinical Immunology, Hôpital du Kremlin-Bicêtre, INSERM, CEA, UMR1184, Le Kremlin-Bicêtre, France. Electronic address: olivier.lambotte@aphp.fr.
Ann Oncol ; 35(6): 569-570, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38548063
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Limite: Humans Idioma: En Revista: Ann Oncol / Ann. oncol / Annals of oncology Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Limite: Humans Idioma: En Revista: Ann Oncol / Ann. oncol / Annals of oncology Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article